BRPI0509529A - forma cristalina de ácido 8-ciano -1-ciclopropil-7-(1s,6s-2,8-diazabiciclo[4.3.0]nonan-8-il)- 6-flúor-1,4-dihidro-4-oxo-3-quinolincarboxìlico - Google Patents

forma cristalina de ácido 8-ciano -1-ciclopropil-7-(1s,6s-2,8-diazabiciclo[4.3.0]nonan-8-il)- 6-flúor-1,4-dihidro-4-oxo-3-quinolincarboxìlico

Info

Publication number
BRPI0509529A
BRPI0509529A BRPI0509529-8A BRPI0509529A BRPI0509529A BR PI0509529 A BRPI0509529 A BR PI0509529A BR PI0509529 A BRPI0509529 A BR PI0509529A BR PI0509529 A BRPI0509529 A BR PI0509529A
Authority
BR
Brazil
Prior art keywords
nonan
cyano
quinolincarboxylic
diazabicyclo
cyclopropyl
Prior art date
Application number
BRPI0509529-8A
Other languages
English (en)
Inventor
Hubert Rast
Iris Heep
Alfons Grunenberg
Werner Hallenbach
Jordi Benet-Buchholz
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of BRPI0509529A publication Critical patent/BRPI0509529A/pt
Publication of BRPI0509529B1 publication Critical patent/BRPI0509529B1/pt
Publication of BRPI0509529B8 publication Critical patent/BRPI0509529B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

FORMA CRISTALINA DE áCIDO 8-CIANO-1-CICLO-PROPIL-7-(1 S,6S-2,8-DIAZABICICLO¢4.3.0!NONAN-8-IL)-6-FLúOR-1,4-DIHIDR O-4-OXO-3-QUINOLINOCARBOXìLICO. A presente invenção refere-se ao trihidrato de pradofloxacina, processos para a sua fabricação, bem como agentes antibacterianos contendo o mesmo.
BRPI0509529A 2004-04-01 2005-03-19 forma cristalina de ácido 8-ciano-1-ciclopropil-7-(1s,6s-2,8-diaza-biciclo[4.3.0]nonan-8-il)-6-flúor-1,4-dihidro-4-oxo-3-quinoli-nocarboxílico, seu uso, e medicamento BRPI0509529B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102004015981.5 2004-04-01
DE102004015981A DE102004015981A1 (de) 2004-04-01 2004-04-01 Neue kirstalline Form von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo[4.3.0]nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure
PCT/EP2005/002953 WO2005097789A1 (de) 2004-04-01 2005-03-19 Neue kristalline form von 8-cyan-1-cyclopropyl-7-(1s,6s-2,8-diazabicyclo[4.3.0]nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure

Publications (3)

Publication Number Publication Date
BRPI0509529A true BRPI0509529A (pt) 2007-09-18
BRPI0509529B1 BRPI0509529B1 (pt) 2019-05-21
BRPI0509529B8 BRPI0509529B8 (pt) 2021-05-25

Family

ID=34962324

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0509529A BRPI0509529B8 (pt) 2004-04-01 2005-03-19 forma cristalina de ácido 8-ciano-1-ciclopropil-7-(1s,6s-2,8-diaza-biciclo[4.3.0]nonan-8-il)-6-flúor-1,4-dihidro-4-oxo-3-quinoli-nocarboxílico, seu uso, e medicamento

Country Status (31)

Country Link
US (1) US7977484B2 (pt)
EP (1) EP1737859B1 (pt)
JP (1) JP5190259B2 (pt)
KR (1) KR101217678B1 (pt)
CN (1) CN100591681C (pt)
AR (2) AR048099A1 (pt)
AT (1) ATE450536T1 (pt)
AU (1) AU2005231918B2 (pt)
BR (1) BRPI0509529B8 (pt)
CA (1) CA2561635C (pt)
CY (2) CY1109762T1 (pt)
DE (3) DE102004015981A1 (pt)
DK (1) DK1737859T3 (pt)
ES (1) ES2335899T3 (pt)
GT (1) GT200500043A (pt)
HR (1) HRP20100097T1 (pt)
IL (1) IL178353A (pt)
MY (1) MY140998A (pt)
NO (1) NO337279B1 (pt)
NZ (1) NZ550226A (pt)
PE (1) PE20060170A1 (pt)
PL (1) PL1737859T3 (pt)
PT (1) PT1737859E (pt)
RU (1) RU2383543C2 (pt)
SI (1) SI1737859T1 (pt)
SV (1) SV2006002070A (pt)
TW (1) TWI350755B (pt)
UA (1) UA84329C2 (pt)
UY (1) UY28828A1 (pt)
WO (1) WO2005097789A1 (pt)
ZA (1) ZA200608072B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006010643A1 (de) 2006-03-08 2007-09-13 Bayer Healthcare Aktiengesellschaft Arzneimittel enthaltend Fluorchinolone
DE102006010642A1 (de) * 2006-03-08 2007-09-27 Bayer Healthcare Aktiengesellschaft Arzneimittelformulierungen, enthaltend Fluorchinolone
DE102007026550A1 (de) 2007-06-08 2008-12-11 Bayer Healthcare Ag Extrudate mit verbesserter Geschmacksmaskierung
MX387370B (es) 2017-02-13 2025-03-18 Elanco Animal Health Gmbh Composición líquida que contiene pradofloxacina.
CN115710267A (zh) * 2022-11-30 2023-02-24 天津大学 一种普拉沙星水合物晶体及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19546249A1 (de) * 1995-12-12 1997-06-19 Bayer Ag Neue Kristallmodifikation des 1-Cyclopropyl-7-([S,S]-2,8-diazabicyclo[4,3,0]non-8-yl)-6-fluor-1,4-dihydro-8-methoxy-4-oxo-3-chinolincarbonsäure Hydrochlorid (CDCH), Verfahren zu dessen Herstellung und diese enthaltende pharmazeutische Zubereitungen
BR9707606B1 (pt) * 1996-02-23 2010-08-10 ácidos 8-ciano-1-ciclopropil-7-(2,8-diazabiciclo(4.3.0) nonan-8-il)-6-flúor-1,4-diidro-4-oxo-3-quinolinocarbo xìlicos, bem como medicamentos que os compreendem.
DE19854357A1 (de) 1998-11-25 2000-05-31 Bayer Ag Semi-Hydrochlorid von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo/4.3.0/ -nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure
DE19854356A1 (de) 1998-11-25 2000-05-31 Bayer Ag Kristallmodifikation A von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo-/4.3.0/nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure
DE19854355A1 (de) * 1998-11-25 2000-05-31 Bayer Ag Kristallmodifikation B von 8-Cyan-1-cyclopropyl-7-(1S, 6S-2,8-diazabicyclo-/4.3.O/nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure
DE19908449A1 (de) 1999-02-26 2000-08-31 Bayer Ag Kristallmodifikation C von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicylo-[4.3.0]nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chino/incarbonsäure
DE19908448A1 (de) 1999-02-26 2000-08-31 Bayer Ag Kristallmodifikation D von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicylo[4.3.0)nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chino incarbonsäure
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs

Also Published As

Publication number Publication date
CA2561635A1 (en) 2005-10-20
BRPI0509529B8 (pt) 2021-05-25
CY2011018I1 (el) 2016-12-14
HRP20100097T1 (hr) 2010-04-30
AR048099A1 (es) 2006-03-29
AU2005231918A1 (en) 2005-10-20
BRPI0509529B1 (pt) 2019-05-21
JP5190259B2 (ja) 2013-04-24
EP1737859A1 (de) 2007-01-03
DK1737859T3 (da) 2010-04-06
NO337279B1 (no) 2016-02-29
ES2335899T3 (es) 2010-04-06
AU2005231918B2 (en) 2011-05-12
KR20070014157A (ko) 2007-01-31
UY28828A1 (es) 2005-11-30
HK1104537A1 (en) 2008-01-18
RU2383543C2 (ru) 2010-03-10
CN100591681C (zh) 2010-02-24
TWI350755B (en) 2011-10-21
GT200500043A (es) 2006-02-17
WO2005097789A1 (de) 2005-10-20
PL1737859T3 (pl) 2010-04-30
SI1737859T1 (sl) 2010-03-31
SV2006002070A (es) 2006-03-15
NO20064988L (no) 2006-10-31
MY140998A (en) 2010-02-12
NZ550226A (en) 2009-11-27
AR105177A2 (es) 2017-09-13
DE502005008620D1 (de) 2010-01-14
DE122011100055I1 (de) 2012-03-15
JP2007530614A (ja) 2007-11-01
CY1109762T1 (el) 2014-09-10
UA84329C2 (en) 2008-10-10
US7977484B2 (en) 2011-07-12
US20080125458A1 (en) 2008-05-29
IL178353A0 (en) 2007-02-11
RU2006138362A (ru) 2008-05-10
PE20060170A1 (es) 2006-04-13
ATE450536T1 (de) 2009-12-15
PT1737859E (pt) 2010-02-03
DE102004015981A1 (de) 2005-10-20
EP1737859B1 (de) 2009-12-02
KR101217678B1 (ko) 2013-01-02
IL178353A (en) 2011-08-31
CN1938304A (zh) 2007-03-28
CA2561635C (en) 2012-10-16
TW200602053A (en) 2006-01-16
ZA200608072B (en) 2008-01-08

Similar Documents

Publication Publication Date Title
WO2015095337A3 (en) PYRAZOLO[1,5-a]PYRIMIDINECARBOXAMIDE DERIVATIVES FOR TREATING COGNITIVE IMPAIRMENT
WO2008003958A3 (en) Fused pyrimido compounds
IL204693A0 (en) Imidazo[1, 2 - a] pyrimidine derivatives for the treatment of diseases such as diabetes
MY156377A (en) 1-heterocycl-1, 5-dihydro-pyrazolo [3 , 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
WO2013077921A3 (en) Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
MX2011005936A (es) Compuestos organicos.
ZA200704392B (en) Antibiotic combinations for providing total solution to the treatment of infections
UA93043C2 (ru) ПРОМЕЖУТОЧНЫЕ СОЕДИНЕНИЯ ДЛЯ ПОЛУЧЕНИЯ ТРАНС-5-ХЛОР-2-МЕТИЛ-2,3,3А,12В-ТЕТРАГИДРО-1Н-ДИБЕНЗ[2,3:6,7]ОКСЕПИНО[4,5-с]ПИРОЛА
ATE424386T1 (de) Pyridin-verbindungen für die behandlung von prostaglandin-vermittelten krankheiten
BRPI0822239A2 (pt) Composto de pirazolo[1,5-a] pirimidina
IL246034B (en) History of [1,2,4]triazolo[1,5-a]pyrimidine as protozoan proteasome inhibitors for the treatment of parasitic diseases such as Jericho
AR105177A2 (es) Forma cristalina de ácido 8-ciano-1-ciclopropil-7-(1s,6s-2,8-diazabiciclo-(4.3.0)nonan-8-il)-6-flúor-1,4-dihidro-4-oxo-3-quinolincarboxílico
MX2014014808A (es) Compuestos triciclicos como inhibidores de kat ii.
WO2007102061A3 (en) Prodrugs of benzoquinolizine-2-carboxylic acid
IS7477A (is) Aðferð við framleiðslu sýrusalts af gemifloxasíni
PL1656340T3 (pl) Sposoby wytwarzania pochodnych kwasu 1-karbamoilocykloalkilokarboksylowego
EP1831171A4 (en) PROCESS FOR THE PREPARATION OF NEW MONTELUKAST SODIUM AMORPHOUS
PL2081934T3 (pl) Proces wytwarzania krystalicznej pirazolo[1,5-a] pirymidyny
ATE393155T1 (de) Neue zwischenprodukte für die herstellung therapeutisch wirksamer imidazopyridine
IL189370A0 (en) PROCESS FOR PRODUCING IMIDAZO[1,2-b]PYRIDAZINE COMPOUND
ATE473219T1 (de) Cholinerge enhancer mit verbesserter durchgängigkeit durch die blut-hirn-schranke zur behandlung von krankheiten, die mit kognitiven störungen einhergehen
HK1100939A (en) Process for the preparation of aryl substituted oxazolidinones as intermediates for antibacterial agents
CY1116567T1 (el) ΕΝΑ ΠΥΡΙΔΙΝΟΚΙΝΟΛΙΝΟ-ΥΠΟΚΑΣΤΕΣΤΗΜΕΝΟ ΜΟΝΟΕΝΥΔΡΟ ΠΥΡΡΟΛΟ [1,2-B]ΠΥΡΑΖΟΛΙΟ ΩΣ ΑΝΑΣΤΟΛΕΑΣ ΤΟΥ TGF-β
ZA200510102B (en) New process for the production of melagatran
PL386966A1 (pl) Sposób wytwarzania mieszaniny diastereoizomerów 1,2,3,4-tetrahydro-1-(3,4-metylenodioksyfenylo)-9H-pirydo[3,4-b]indolo-3-karboksylanu metylu z przewagą diastereoizomeru(1R,3R)

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: BAYER ANIMAL HEALTH GMBH (DE)

Free format text: TRANSFERIDO DE: BAYER HEALTHCARE AG

B25A Requested transfer of rights approved

Owner name: BAYER INTELLECTUAL PROPERTY GMBH (DE)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 21/05/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 21/05/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/03/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B22E Other requirements [chapter 22.5 patent gazette]

Free format text: FORMULADA EXIGENCIA PARA ADEQUACAO OU CUMPRIMENTO DE DISPOSICOES LEGAIS NO PRAZO DE 60 (SESSENTA) DIAS DESTA DATA.

B16B Notification of grant cancelled [chapter 16.2 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 16.3 NA RPI NO 2629 DE 25/05/2021 POR TER SIDO INDEVIDA.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: RETIFICACAO REF. RPI 2524, DE 21/05/2019. PRAZO DE VALIDADE: 10 ANOS CONTADOS A PARTIR DE 21/05/2019, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME A ADI 5.529/DF, COM APOSTILAMENTO DO PRAZO DE VALIDADE DA PROTECAO DA MATERIA RELATIVA A PRODUTOS E PROCESSOS FARMACEUTICOS E EQUIPAMENTOS E/OU MATERIAIS DE USO EM SAUDE, PARA APLICACAO EM HUMANOS.

B25G Requested change of headquarter approved

Owner name: BAYER INTELLECTUAL PROPERTY GMBH (DE)

B25A Requested transfer of rights approved

Owner name: BAYER ANIMAL HEALTH GMBH (DE)

B25D Requested change of name of applicant approved

Owner name: ELANCO ANIMAL HEALTH GMBH (DE)

B25G Requested change of headquarter approved

Owner name: ELANCO ANIMAL HEALTH GMBH (DE)